A Phase 4 Randomized OpenLabel Trial to Describe the Safety Tolerability and Immunogenicity of 13 Valent Pneumococcal Conjugate Vaccine Formulated in Multidose Vials When Given With Routine Pediatric Vaccines in Healthy Infants in India.
Not yet recruiting
Phase of Trial: Phase IV
Latest Information Update: 12 Feb 2018
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Pfizer
- 30 Jan 2018 Planned initiation date changed from 21 Nov 2017 to 2 Apr 2018.
- 12 Dec 2017 New trial record